Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;26(2):174-82.
doi: 10.3978/j.issn.1000-9604.2014.04.02.

A preliminary report on adjuvant analgesic efficacy of HANS in opioid tolerant patients with cancer pain

Xiaomei Li  1 , Jianhua Zhu  1 , Pingping Li  1 , Guangqing Zhu  1 , Xiaoming Wu  1 , Huoming Chen  1 , Huixia Zhao  1 , Wei Wang  1 , Ying Zhang  1 , Wenhua Xiao  1 , Duanqi Liu  1
Affiliations

A preliminary report on adjuvant analgesic efficacy of HANS in opioid tolerant patients with cancer pain

Xiaomei Li et al. Chin J Cancer Res. 2014 Apr.

Abstract

Objective: To observe the adjuvant analgesic efficacy of Han's Acupoint Nerve Stimulator (HANS) in opioid tolerant patients with cancer pain.

Methods: A prospective non-controlled study was conducted. Opioid tolerant patients with cancer pain were enrolled and treated with both routinely analgesics and adjuvant HANS (2/100 Hz for 30 min/d, 5 d on and 2 d off for two weeks). Cancer pain, quality of life (QOL), anxiety and depression were assessed before enrollment and on d 8 and d 15 with the BPI-C, EORTC QLQ-C30, and self-rating anxiety scale (SAS)/self-rating depression scale (SDS), respectively; the therapeutic frequency of breakthrough pain (BP) and daily opioid dose were also recorded.

Results: Totally 47 patients meeting the inclusion criteria participated in this study; 43 patients completed the two-week treatment and assessment. The mean scores of patient's "worst" and "least" pain intensity assessed with BPI-C decreased significantly on d 8 and d 15; the therapeutic frequency of BP also significantly decreased; but the average daily dose of opioids did not change significantly. For the nine symptoms in EORTC QLQ-C30 assessment, the mean scores of pain, fatigue, constipation and insomnia were significantly lower on d 8 and d 15 compared with baseline; the mean scores of the overall health status, nausea/vomiting and the incidence rates of both anxiety and depression also decreased significantly on d 15.

Conclusions: To opioid tolerant patients with cancer pain, adjuvant treatment with HANS could improve pain release and patients' QOL by decreasing the severity of pain, fatigue, constipation, insomnia and other concomitant symptoms; it could also decrease the incidence rates of anxiety and depression.

Keywords: Cancer pain; Han’s Acupoint Nerve Stimulator (HANS); opioid tolerance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient flow. HANS, Han’s Acupoint Nerve Stimulator.
See this image and copyright information in PMC

References

    1. Swarm RA, Abernethy AP, Anghelescu DL, et al. Adult cancer pain. J Natl Compr Canc Netw 2013;11:992-1022 - PMC - PubMed
    1. Deandrea S, Montanari M, Moja L, et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008;19:1985-91 - PMC - PubMed
    1. Fisch MJ, Lee JW, Weiss M, et al. Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. J Clin Oncol 2012;30:1980-8 - PMC - PubMed
    1. Collett BJ. Opioid tolerance: the clinical perspective. Br J Anaesth 1998;81:58-68 - PubMed
    1. Kurz A, Sessler DI. Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 2003;63:649-71 - PubMed